Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.

Kende M, Paragas J, Salazar AM.

Antiviral Res. 2019 Mar;163:179-184. doi: 10.1016/j.antiviral.2018.12.020. Epub 2019 Jan 3.

PMID:
30611774
2.

Charting a Course for Precision Oncology.

Kusnezov D, Paragas J.

Clin Pharmacol Ther. 2017 May;101(5):593-594. doi: 10.1002/cpt.654. Review.

PMID:
28182275
3.

Systems biology for organotypic cell cultures.

Grego S, Dougherty ER, Alexander FJ, Auerbach SS, Berridge BR, Bittner ML, Casey W, Cooley PC, Dash A, Ferguson SS, Fennell TR, Hawkins BT, Hickey AJ, Kleensang A, Liebman MNJ, Martin F, Maull EA, Paragas J, Qiao GG, Ramaiahgari S, Sumner SJ, Yoon M.

ALTEX. 2017;34(2):301-310. doi: 10.14573/altex.1608221. Epub 2016 Nov 14.

4.

Sepsis and Presidential Initiatives.

Cohen M, Falcone P, Kusnezov D, Paragas J.

Crit Care Med. 2016 Nov;44(11):1963-1965. No abstract available.

PMID:
27755067
5.

Roger Gerrard Breeze, 1946-2016.

Paragas J, Dudley J, Karesh W, Leighton T, Rudolph A.

Health Secur. 2016 Jul-Aug;14(4):203-4. doi: 10.1089/hs.2016.0061. Epub 2016 Jul 21. No abstract available.

PMID:
27442909
6.

A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus.

Das S, Rundell MS, Mirza AH, Pingle MR, Shigyo K, Garrison AR, Paragas J, Smith SK, Olson VA, Larone DH, Spitzer ED, Barany F, Golightly LM.

PLoS One. 2015 Sep 18;10(9):e0138484. doi: 10.1371/journal.pone.0138484. eCollection 2015.

7.

The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.

Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG Jr, McMahon JB, Huggins J, O'Keefe BR.

Antiviral Res. 2014 Dec;112:1-7. doi: 10.1016/j.antiviral.2014.09.012. Epub 2014 Oct 5.

8.

Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL.

J Infect Dis. 2013 Jul 15;208(2):310-8. doi: 10.1093/infdis/jis921. Epub 2012 Dec 18.

9.

Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.

Altmann SE, Smith AL, Dyall J, Johnson RF, Dodd LE, Jahrling PB, Paragas J, Blaney JE.

Antiviral Res. 2012 Feb;93(2):305-308. doi: 10.1016/j.antiviral.2011.12.001. Epub 2011 Dec 11.

10.

Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease.

Johnson RF, Dodd LE, Yellayi S, Gu W, Cann JA, Jett C, Bernbaum JG, Ragland DR, St Claire M, Byrum R, Paragas J, Blaney JE, Jahrling PB.

Virology. 2011 Dec 20;421(2):129-40. doi: 10.1016/j.virol.2011.09.016. Epub 2011 Oct 19.

11.

Evaluation of monkeypox disease progression by molecular imaging.

Dyall J, Johnson RF, Chen DY, Huzella L, Ragland DR, Mollura DJ, Byrum R, Reba RC, Jennings G, Jahrling PB, Blaney JE, Paragas J.

J Infect Dis. 2011 Dec 15;204(12):1902-11. doi: 10.1093/infdis/jir663. Epub 2011 Oct 19.

12.

Intrabronchial inoculation of cynomolgus macaques with cowpox virus.

Smith AL, St Claire M, Yellayi S, Bollinger L, Jahrling PB, Paragas J, Blaney JE, Johnson RF.

J Gen Virol. 2012 Jan;93(Pt 1):159-64. doi: 10.1099/vir.0.036905-0. Epub 2011 Sep 21.

13.

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ.

J Virol. 2011 Oct;85(20):10605-16. doi: 10.1128/JVI.00558-11. Epub 2011 Aug 17.

14.

Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.

Johnson RF, Yellayi S, Cann JA, Johnson A, Smith AL, Paragas J, Jahrling PB, Blaney JE.

Virology. 2011 Sep 30;418(2):102-12. doi: 10.1016/j.virol.2011.07.013. Epub 2011 Aug 15.

15.

Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein.

Goff A, Mucker E, Raymond J, Fisher R, Bray M, Hensley L, Paragas J.

Arch Virol. 2011 Oct;156(10):1877-81. doi: 10.1007/s00705-011-1065-1. Epub 2011 Aug 4.

PMID:
21814864
16.

Molecular imaging of influenza and other emerging respiratory viral infections.

Bray M, Lawler J, Paragas J, Jahrling PB, Mollura DJ.

J Infect Dis. 2011 May 15;203(10):1348-59. doi: 10.1093/infdis/jir038. Epub 2011 Mar 21. Review.

17.

A novel respiratory model of infection with monkeypox virus in cynomolgus macaques.

Goff AJ, Chapman J, Foster C, Wlazlowski C, Shamblin J, Lin K, Kreiselmeier N, Mucker E, Paragas J, Lawler J, Hensley L.

J Virol. 2011 May;85(10):4898-909. doi: 10.1128/JVI.02525-10. Epub 2011 Mar 9.

18.

Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.

Johnson RF, Dyall J, Ragland DR, Huzella L, Byrum R, Jett C, St Claire M, Smith AL, Paragas J, Blaney JE, Jahrling PB.

J Virol. 2011 Mar;85(5):2112-25. doi: 10.1128/JVI.01931-10. Epub 2010 Dec 8.

19.

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB.

PLoS Pathog. 2008 Nov;4(11):e1000225. doi: 10.1371/journal.ppat.1000225. Epub 2008 Nov 28.

20.

Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.

Subramanian GM, Moore PA, Gowen BB, Olsen AL, Barnard DL, Paragas J, Hogan RJ, Sidwell RW.

Chemotherapy. 2008;54(3):176-80. doi: 10.1159/000140361. Epub 2008 Jun 18.

PMID:
18560223
21.

Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses.

Frias-Staheli N, Giannakopoulos NV, Kikkert M, Taylor SL, Bridgen A, Paragas J, Richt JA, Rowland RR, Schmaljohn CS, Lenschow DJ, Snijder EJ, García-Sastre A, Virgin HW 4th.

Cell Host Microbe. 2007 Dec 13;2(6):404-16.

22.

Lymphocyte death in a mouse model of Ebola virus infection.

Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, Garrison A, Hensley LE, Geisbert TW.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S296-304.

PMID:
17940964
23.

Development of a TaqMan minor groove binding protein assay for the detection and quantification of Crimean-Congo hemorrhagic fever virus.

Garrison AR, Alakbarova S, Kulesh DA, Shezmukhamedova D, Khodjaev S, Endy TP, Paragas J.

Am J Trop Med Hyg. 2007 Sep;77(3):514-20.

PMID:
17827370
24.

In vivo imaging of cidofovir treatment of cowpox virus infection.

Goff A, Twenhafel N, Garrison A, Mucker E, Lawler J, Paragas J.

Virus Res. 2007 Sep;128(1-2):88-98. Epub 2007 May 23.

PMID:
17524511
25.

Pathogenesis and sepsis caused by organisms potentially utilized as biologic weapons: opportunities for targeted intervention.

Hepburn MJ, Purcell BK, Paragas J.

Curr Drug Targets. 2007 Apr;8(4):519-32. Review.

PMID:
17430123
26.

Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein.

Altamura LA, Bertolotti-Ciarlet A, Teigler J, Paragas J, Schmaljohn CS, Doms RW.

J Virol. 2007 Jun;81(12):6632-42. Epub 2007 Apr 4.

27.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

28.

Permeabilization of the plasma membrane by Ebola virus GP2.

Han Z, Licata JM, Paragas J, Harty RN.

Virus Genes. 2007 Jun;34(3):273-81. Epub 2006 Aug 22.

PMID:
16927113
29.

Laboratory transmission of Japanese encephalitis and West Nile viruses by molestus form of Culex pipiens (Diptera: Culicidae) collected in Uzbekistan in 2004.

Turell MJ, Mores CN, Dohm DJ, Komilov N, Paragas J, Lee JS, Shermuhemedova D, Endy TP, Kodirov A, Khodjaev S.

J Med Entomol. 2006 Mar;43(2):296-300.

PMID:
16619614
30.

Cynomolgus macaque as an animal model for severe acute respiratory syndrome.

Lawler JV, Endy TP, Hensley LE, Garrison A, Fritz EA, Lesar M, Baric RS, Kulesh DA, Norwood DA, Wasieloski LP, Ulrich MP, Slezak TR, Vitalis E, Huggins JW, Jahrling PB, Paragas J.

PLoS Med. 2006 May;3(5):e149. Epub 2006 Apr 18.

31.

Development of treatment strategies to combat Ebola and Marburg viruses.

Paragas J, Geisbert TW.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):67-76. Review.

PMID:
16441210
32.

Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus.

Ahmed AA, McFalls JM, Hoffmann C, Filone CM, Stewart SM, Paragas J, Khodjaev S, Shermukhamedova D, Schmaljohn CS, Doms RW, Bertolotti-Ciarlet A.

J Gen Virol. 2005 Dec;86(Pt 12):3327-36.

PMID:
16298978
33.

A survey of antiviral drugs for bioweapons.

Goff AJ, Paragas J.

Antivir Chem Chemother. 2005;16(5):283-94. Review.

PMID:
16245644
34.

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models.

Paragas J, Blatt LM, Hartmann C, Huggins JW, Endy TP.

Antiviral Res. 2005 Jun;66(2-3):99-102. Epub 2005 Feb 15.

PMID:
15911026
35.

Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.

Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J, Altamura LA, McFalls JM, Frias-Stäheli N, García-Sastre A, Schmaljohn CS, Doms RW.

J Virol. 2005 May;79(10):6152-61.

36.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.

Virology. 2005 Feb 5;332(1):20-7.

37.

Experimental transmission of Karshi and Langat (tick-borne encephalitis virus complex) viruses by Ornithodoros ticks (Acari: Argasidae).

Turell MJ, Mores CN, Lee JS, Paragas JJ, Shermuhemedova D, Endy TP, Khodjaev S.

J Med Entomol. 2004 Sep;41(5):973-7.

PMID:
15535630
38.

Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1.

Hogan RJ, Gao G, Rowe T, Bell P, Flieder D, Paragas J, Kobinger GP, Wivel NA, Crystal RG, Boyer J, Feldmann H, Voss TG, Wilson JM.

J Virol. 2004 Oct;78(20):11416-21.

39.

A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.

Paragas J, Whitehouse CA, Endy TP, Bray M.

Antiviral Res. 2004 Apr;62(1):21-5.

PMID:
15026198
40.

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP.

Lancet. 2003 Dec 13;362(9400):1953-8.

PMID:
14683653
41.

Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.

Mahanty S, Gupta M, Paragas J, Bray M, Ahmed R, Rollin PE.

Virology. 2003 Aug 1;312(2):415-24.

42.

The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, Klenk HD, Palese P, García-Sastre A.

J Virol. 2003 Jul;77(14):7945-56.

43.
44.
45.

Experimental therapy of filovirus infections.

Bray M, Paragas J.

Antiviral Res. 2002 Apr;54(1):1-17. Review. No abstract available.

PMID:
11888653
46.

Influenza B and C virus NEP (NS2) proteins possess nuclear export activities.

Paragas J, Talon J, O'Neill RE, Anderson DK, García-Sastre A, Palese P.

J Virol. 2001 Aug;75(16):7375-83.

47.

The Ebola virus VP35 protein functions as a type I IFN antagonist.

Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, García-Sastre A, Palese P.

Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94.

48.
50.

Supplemental Content

Loading ...
Support Center